Waverley Pharma (5GZ) Stock Overview
A biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
5GZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Waverley Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.008 |
| 52 Week High | CA$0.014 |
| 52 Week Low | CA$0.004 |
| Beta | 1.84 |
| 1 Month Change | 33.33% |
| 3 Month Change | -20.00% |
| 1 Year Change | 23.08% |
| 3 Year Change | -72.41% |
| 5 Year Change | -91.92% |
| Change since IPO | -91.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.06% | 2.7% |
| 1Y | 23.1% | -28.8% | 14.5% |
Return vs Industry: 5GZ exceeded the German Biotechs industry which returned -28.8% over the past year.
Return vs Market: 5GZ exceeded the German Market which returned 14.5% over the past year.
Price Volatility
| 5GZ volatility | |
|---|---|
| 5GZ Average Weekly Movement | 27.9% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5GZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5GZ's weekly volatility has decreased from 41% to 28% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Larry Thiessen | www.waverleypharma.com |
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States.
Waverley Pharma Inc. Fundamentals Summary
| 5GZ fundamental statistics | |
|---|---|
| Market cap | €659.32k |
| Earnings (TTM) | -€245.44k |
| Revenue (TTM) | €764.52k |
Is 5GZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GZ income statement (TTM) | |
|---|---|
| Revenue | CA$1.25m |
| Cost of Revenue | CA$712.05k |
| Gross Profit | CA$540.26k |
| Other Expenses | CA$942.30k |
| Earnings | -CA$402.04k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0074 |
| Gross Margin | 43.14% |
| Net Profit Margin | -32.10% |
| Debt/Equity Ratio | -136.7% |
How did 5GZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 01:35 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Waverley Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.